Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Midatech Pharma Plc - news published 64 - readings 2.395

BACK

Midatech Pharma plc

New Preclinical R&D Programme Focused on Leptomeningeal Disease - Form 6-K

New Preclinical R&D Programme Focused on Leptomeningeal Disease Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs. B ...

27.03.2023

Midatech Pharma plc

R&D Programme Focused on Leptomeningeal Disease

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 27 March 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 27 March 2023 12:05:12 UTC .

27.03.2023

Midatech Pharma plc

Notice of Effectiveness - Form EFFECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: March 24, 2023 4:00 P.M. Form: F-1 CIK: 0001643918 Company Name: Midatech Pharma Plc File Number: 333-270353 Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 24 March 2023 and is solely responsible for ...

27.03.2023

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 24 March 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 24 March 2023 21:20:08 UTC .

24.03.2023

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT MIDATECH PHARMA PLC 9,888,640 Ordinary Shares Representing 1,977,728 American Depositary Shares This prospectus supplement (the "Prospectus Supplement") amends and supplements our prospectus contained in our Post-Effective Amendment No. 2 to our Registration Statement on Form F-1, eff ...

24.03.2023

Midatech Pharma plc

Results of General Meeting - Form 6-K

Results of General Meeting Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the ...

24.03.2023

Midatech Pharma plc

Results of General Meeting

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 24 March 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 24 March 2023 11:46:28 UTC .

24.03.2023

Midatech Pharma plc

Further re: Notice of General Meeting - Correction of Typographical Errors - Form 6-K

Further re : Notice of General Meeting - Correction of Typographical Errors Further to the announcement made on 8 March 2023 providing notice of a general meeting (the " GM ") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the " Notice &qu ...

10.03.2023

Midatech Pharma plc

Further re: Notice of General Meeting

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 10 March 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 March 2023 18:10:04 UTC .

10.03.2023

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

08.03.2023

Midatech Pharma plc

Registration Statement by Foreign Issuer - Form F-1

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Midatech Pharma plc published this content on 08 March 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 08 March 2023 21:15:34 UTC .

08.03.2023

Midatech Pharma plc

Proposed authority to allot Ordinary Shares and to disapply pre-emption rights Proposed change of name to Biodexa Pharmaceuticals PLC Proposed adoption of the New Articles - Form 6-K

Proposed authority to allot Ordinary Shares and to disapply pre-emption rights Proposed change of name to Biodexa Pharmaceuticals PLC Proposed adoption of the New Articles Proposed Cancellation of Admission of the Ordinary Shares to Trading on AIM and Notice of General Meeting Strand Hanson Limited ("Strand Hanson"), which is authorised and regulated in the United Ki ...

08.03.2023

Midatech Pharma plc

FAQs regarding proposed AIM cancellation

FREQUENTLY ASKED QUESTIONS REGARDING ORDINARY SHARES, ADSs AND THE PROPOSED AIM CANCELLATION WHAT IS THE RELATIONSHIP BETWEEN MIDATECH PHARMA PLC'S (" MIDATECH ") ORDINARY SHARES AND AMERICAN DEPOSITARY SHARES (" ADSs ")? Each ADS is a tradeable security representing twenty-ﬁve (25) ordinary shares of currently £0.001 nominal value each in the capital of ...

08.03.2023

Midatech Pharma plc

Shareholder Circular and Notice of General Meeting to be held on 24 March 2023

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or as to what action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent professional adviser duly authorised for the purposes of the Financial Services and Markets Act 2000 (as amen ...

08.03.2023

Midatech Pharma plc

Notice of Sales of Unregistered Securities - Form D

SEC FORM D The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Nu ...

17.02.2023

Midatech Pharma Plc - news published 64 - readings 2.395

Midatech Pharma plc

New Preclinical R&D Programme Focused on Leptomeningeal Disease - Form 6-K

Midatech Pharma plc

R&D Programme Focused on Leptomeningeal Disease

Midatech Pharma plc

Notice of Effectiveness - Form EFFECT

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Results of General Meeting - Form 6-K

Midatech Pharma plc

Results of General Meeting

Midatech Pharma plc

Further re: Notice of General Meeting - Correction of Typographical Errors - Form 6-K

Midatech Pharma plc

Further re: Notice of General Meeting

Midatech Pharma plc

Supplemental Prospectus - Form 424B3

Midatech Pharma plc

Registration Statement by Foreign Issuer - Form F-1

Midatech Pharma plc

Proposed authority to allot Ordinary Shares and to disapply pre-emption rights Proposed change of name to Biodexa Pharmaceuticals PLC Proposed adoption of the New Articles - Form 6-K

Midatech Pharma plc

FAQs regarding proposed AIM cancellation

Midatech Pharma plc

Shareholder Circular and Notice of General Meeting to be held on 24 March 2023

Midatech Pharma plc

Notice of Sales of Unregistered Securities - Form D

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member